Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type' n4 o& ]+ h4 D+ T; Q) R
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
5 c* j' ^0 R8 o+ Author Affiliations3 o& D6 x$ }( U" k) I
* _" I; E# M/ F- A; j1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
$ Z4 x0 o# v& J8 O2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan $ \+ ?3 \! B D
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan M2 T6 F0 ~2 x* {* R
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 0 N, i* ]8 u1 p: h h
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 5 T& w3 E* d! c( c. T
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
9 e7 v; J P( ?: P+ ~7 e7Kinki University School of Medicine, Osaka 589-8511, Japan & F/ f" u; p- k: h/ R& d! k1 ]
8Izumi Municipal Hospital, Osaka 594-0071, Japan
* K! ] s6 \; d* \+ R. u- G w, o1 M9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
5 o+ B" i2 W& ~& I! u2 wCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 8 d: _3 x& a- n! | N
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ! C, \" N- S- C) u; J
5 @8 _ Z6 Q3 U: q ~ |